NASDAQ:HAPP

Happiness Biotech Group Competitors

$1.84
-0.01 (-0.54 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.79
Now: $1.84
$1.85
50-Day Range
$1.84
MA: $2.01
$2.13
52-Week Range
$1.63
Now: $1.84
$3.32
Volume154,939 shs
Average Volume1.06 million shs
Market Capitalization$47.53 million
P/E RatioN/A
Dividend YieldN/A
Beta0.6

Competitors

Happiness Biotech Group (NASDAQ:HAPP) Vs. CGC, APHA, CRON, TLRY, USNA, and ACB

Should you be buying HAPP stock or one of its competitors? Companies in the industry of "medicinals & botanicals" are considered alternatives and competitors to Happiness Biotech Group, including Canopy Growth (CGC), Aphria (APHA), Cronos Group (CRON), Tilray (TLRY), USANA Health Sciences (USNA), and Aurora Cannabis (ACB).

Canopy Growth (NASDAQ:CGC) and Happiness Biotech Group (NASDAQ:HAPP) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, dividends and earnings.

Risk & Volatility

Canopy Growth has a beta of 2.44, indicating that its stock price is 144% more volatile than the S&P 500. Comparatively, Happiness Biotech Group has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500.

Profitability

This table compares Canopy Growth and Happiness Biotech Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Canopy Growth-312.84%-13.11%-9.66%
Happiness Biotech GroupN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Canopy Growth and Happiness Biotech Group, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Canopy Growth510211.94
Happiness Biotech Group0000N/A

Canopy Growth presently has a consensus price target of $35.6778, suggesting a potential upside of 28.34%. Given Canopy Growth's higher possible upside, research analysts plainly believe Canopy Growth is more favorable than Happiness Biotech Group.

Insider & Institutional Ownership

10.2% of Canopy Growth shares are held by institutional investors. Comparatively, 1.6% of Happiness Biotech Group shares are held by institutional investors. 0.3% of Canopy Growth shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Canopy Growth and Happiness Biotech Group's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Canopy Growth$297.34 million35.73$-993,370,000.00$1.3221.06
Happiness Biotech Group$65.06 million0.73$12.69 millionN/AN/A

Happiness Biotech Group has lower revenue, but higher earnings than Canopy Growth.

Summary

Canopy Growth beats Happiness Biotech Group on 8 of the 12 factors compared between the two stocks.

Happiness Biotech Group (NASDAQ:HAPP) and Aphria (NASDAQ:APHA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Insider and Institutional Ownership

1.6% of Happiness Biotech Group shares are owned by institutional investors. Comparatively, 10.3% of Aphria shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Happiness Biotech Group and Aphria's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Happiness Biotech GroupN/AN/AN/A
Aphria-36.10%-2.30%-1.66%

Valuation and Earnings

This table compares Happiness Biotech Group and Aphria's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Happiness Biotech Group$65.06 million0.73$12.69 millionN/AN/A
Aphria$405.96 million11.03$-63,210,000.00($0.06)-235.67

Happiness Biotech Group has higher earnings, but lower revenue than Aphria.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Happiness Biotech Group and Aphria, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Happiness Biotech Group0000N/A
Aphria05302.38

Aphria has a consensus price target of $22.00, suggesting a potential upside of 55.59%. Given Aphria's higher probable upside, analysts plainly believe Aphria is more favorable than Happiness Biotech Group.

Risk & Volatility

Happiness Biotech Group has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Comparatively, Aphria has a beta of 2.67, suggesting that its share price is 167% more volatile than the S&P 500.

Summary

Aphria beats Happiness Biotech Group on 6 of the 10 factors compared between the two stocks.

Cronos Group (NASDAQ:CRON) and Happiness Biotech Group (NASDAQ:HAPP) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Profitability

This table compares Cronos Group and Happiness Biotech Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cronos Group266.31%-1.61%-1.41%
Happiness Biotech GroupN/AN/AN/A

Valuation and Earnings

This table compares Cronos Group and Happiness Biotech Group's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos Group$25.64 million117.46$1.17 billion$0.6712.48
Happiness Biotech Group$65.06 million0.73$12.69 millionN/AN/A

Cronos Group has higher earnings, but lower revenue than Happiness Biotech Group.

Risk and Volatility

Cronos Group has a beta of 2.07, indicating that its share price is 107% more volatile than the S&P 500. Comparatively, Happiness Biotech Group has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Cronos Group and Happiness Biotech Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cronos Group24101.86
Happiness Biotech Group0000N/A

Cronos Group presently has a consensus target price of $8.75, suggesting a potential upside of 4.67%. Given Cronos Group's higher probable upside, analysts clearly believe Cronos Group is more favorable than Happiness Biotech Group.

Insider & Institutional Ownership

11.8% of Cronos Group shares are owned by institutional investors. Comparatively, 1.6% of Happiness Biotech Group shares are owned by institutional investors. 7.9% of Cronos Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Cronos Group beats Happiness Biotech Group on 8 of the 11 factors compared between the two stocks.

Tilray (NASDAQ:TLRY) and Happiness Biotech Group (NASDAQ:HAPP) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Tilray and Happiness Biotech Group, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tilray19001.90
Happiness Biotech Group0000N/A

Tilray presently has a consensus target price of $18.3078, indicating a potential upside of 6.44%. Given Tilray's higher possible upside, equities analysts clearly believe Tilray is more favorable than Happiness Biotech Group.

Insider and Institutional Ownership

12.6% of Tilray shares are held by institutional investors. Comparatively, 1.6% of Happiness Biotech Group shares are held by institutional investors. 16.8% of Tilray shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Tilray has a beta of 3.12, indicating that its stock price is 212% more volatile than the S&P 500. Comparatively, Happiness Biotech Group has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500.

Profitability

This table compares Tilray and Happiness Biotech Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tilray-242.60%-92.70%-20.70%
Happiness Biotech GroupN/AN/AN/A

Valuation and Earnings

This table compares Tilray and Happiness Biotech Group's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tilray$166.98 million17.69$-321,170,000.00($1.69)-10.18
Happiness Biotech Group$65.06 million0.73$12.69 millionN/AN/A

Happiness Biotech Group has lower revenue, but higher earnings than Tilray.

Summary

Tilray beats Happiness Biotech Group on 6 of the 10 factors compared between the two stocks.

USANA Health Sciences (NYSE:USNA) and Happiness Biotech Group (NASDAQ:HAPP) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.

Valuation and Earnings

This table compares USANA Health Sciences and Happiness Biotech Group's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
USANA Health Sciences$1.06 billion1.92$100.53 million$4.4122.42
Happiness Biotech Group$65.06 million0.73$12.69 millionN/AN/A

USANA Health Sciences has higher revenue and earnings than Happiness Biotech Group.

Analyst Ratings

This is a breakdown of recent ratings for USANA Health Sciences and Happiness Biotech Group, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
USANA Health Sciences00203.00
Happiness Biotech Group0000N/A

USANA Health Sciences presently has a consensus price target of $126.00, indicating a potential upside of 27.41%. Given USANA Health Sciences' higher probable upside, research analysts plainly believe USANA Health Sciences is more favorable than Happiness Biotech Group.

Profitability

This table compares USANA Health Sciences and Happiness Biotech Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
USANA Health Sciences10.57%32.91%22.26%
Happiness Biotech GroupN/AN/AN/A

Institutional & Insider Ownership

54.1% of USANA Health Sciences shares are owned by institutional investors. Comparatively, 1.6% of Happiness Biotech Group shares are owned by institutional investors. 45.4% of USANA Health Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

USANA Health Sciences has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Happiness Biotech Group has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500.

Summary

USANA Health Sciences beats Happiness Biotech Group on 11 of the 11 factors compared between the two stocks.

Aurora Cannabis (NYSE:ACB) and Happiness Biotech Group (NASDAQ:HAPP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Profitability

This table compares Aurora Cannabis and Happiness Biotech Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aurora Cannabis-1,238.94%-16.32%-13.12%
Happiness Biotech GroupN/AN/AN/A

Institutional and Insider Ownership

11.9% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 1.6% of Happiness Biotech Group shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for Aurora Cannabis and Happiness Biotech Group, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aurora Cannabis69001.60
Happiness Biotech Group0000N/A

Aurora Cannabis presently has a consensus price target of $10.9264, suggesting a potential upside of 38.66%. Given Aurora Cannabis' higher possible upside, analysts clearly believe Aurora Cannabis is more favorable than Happiness Biotech Group.

Earnings & Valuation

This table compares Aurora Cannabis and Happiness Biotech Group's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora Cannabis$207.89 million7.50$-2,468,190,000.00($2.86)-2.76
Happiness Biotech Group$65.06 million0.73$12.69 millionN/AN/A

Happiness Biotech Group has lower revenue, but higher earnings than Aurora Cannabis.

Risk and Volatility

Aurora Cannabis has a beta of 3.44, meaning that its share price is 244% more volatile than the S&P 500. Comparatively, Happiness Biotech Group has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.

Summary

Aurora Cannabis beats Happiness Biotech Group on 5 of the 9 factors compared between the two stocks.


Happiness Biotech Group Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Canopy Growth logo
CGC
Canopy Growth
1.0$27.80-1.4%$10.62 billion$297.34 million-8.32News Coverage
Aphria logo
APHA
Aphria
1.6$14.14-3.9%$4.48 billion$405.96 million-23.97Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
Gap Up
Cronos Group logo
CRON
Cronos Group
0.8$8.36-2.6%$3.01 billion$25.64 million34.83Analyst Downgrade
Tilray logo
TLRY
Tilray
1.0$17.20-1.5%$2.95 billion$166.98 million-3.79News Coverage
USANA Health Sciences logo
USNA
USANA Health Sciences
2.0$98.89-2.6%$2.04 billion$1.06 billion18.31Analyst Downgrade
Aurora Cannabis logo
ACB
Aurora Cannabis
1.5$7.88-1.1%$1.56 billion$207.89 million-0.32Analyst Downgrade
Sundial Growers logo
SNDL
Sundial Growers
1.0$0.85-1.2%$1.41 billion$75.86 million-0.33Analyst Upgrade
Gap Up
HEXO logo
HEXO
HEXO
1.1$5.52-3.3%$676.12 million$60.46 million-1.13Gap Up
ChromaDex logo
CDXC
ChromaDex
1.3$8.20-4.0%$547.41 million$46.29 million-21.58
MediWound logo
MDWD
MediWound
1.4$5.04-2.0%$137.27 million$31.79 million-12.60Decrease in Short Interest
Natural Alternatives International logo
NAII
Natural Alternatives International
0.4$18.20-6.3%$115.72 million$118.88 million227.53High Trading Volume
Increase in Short Interest
Gap Up
Mannatech logo
MTEX
Mannatech
1.3$19.13-2.4%$39.58 million$157.73 million5.89Gap Down
FSD Pharma logo
HUGE
FSD Pharma
0.3$1.56-1.9%$29.89 million$190,000.00-0.35Increase in Short Interest
News Coverage
CYAN
Cyanotech
0.6$3.14-1.6%$19.15 million$31.90 million31.40
This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.